Correcting anemia in heart failure: The efficacy and safety of erythropoiesis-stimulating agents

Journal of Cardiac Failure

Volumn 16, Issue 8, 2010, Pages 649-658

  Lawler, Patrick R ^a,b   Filion, Kristian B ^c   Eisenberg, Mark J ^a,d  

^a MCGILL UNIVERSITY   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

^c UNIVERSITY OF MINNESOTA   (United States)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

anemia; chronic heart failure; darbepoetin; Erythropoiesis stimulating agents; erythropoietin; hemantics

Indexed keywords

BETA ERYTHROPOIETIN; BRAIN NATRIURETIC PEPTIDE; ERYTHROPOIETIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; UNCLASSIFIED DRUG;

ANEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; EXERCISE TOLERANCE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; HYPERTENSION; PERFORMANCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEIZURE; TRANSIENT ISCHEMIC ATTACK; VEIN THROMBOSIS;

ANEMIA; ANIMALS; HEART FAILURE; HEMATINICS; HUMANS; RANDOM ALLOCATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 77955516673     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2010.03.013     Document Type: Review

References (47)

1. Y.D. Tang, and S.D. Katz The prevalence of anemia in chronic heart failure and its impact on the clinical outcomes Heart Fail Rev 13 2008 387 392
2. H. Tanner, G. Moschovitis, G.M. Kuster, R. Hullin, D. Pfiiffner, and O.M. Hess The prevalence of anemia in chronic heart failure Int J Cardiol 86 2002 115 121
3. I.S. Anand Anemia and chronic heart failure implications and treatment options J Am Coll Cardiol 52 2008 501 511
4. Y.D. Tang, and S.D. Katz Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options Circulation 113 2006 2454 2461
5. A. Kazory, and E.A. Ross Anemia: the point of convergence or divergence for kidney disease and heart failure? J Am Coll Cardiol 53 2009 639 647
6. C. Ronco, M. Haapio, A.A. House, N. Anavekar, and R. Bellomo Cardiorenal syndrome J Am Coll Cardiol 52 2008 1527 1539
7. I. Anand, J.J. McMurray, J. Whitmore, M. Warren, A. Pham, and M.A. McCamish Anemia and its relationship to clinical outcome in heart failure Circulation 110 2004 149 154
8. T.B. Horwich, G.C. Fonarow, M.A. Hamilton, W.R. MacLellan, and J. Borenstein Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure J Am Coll Cardiol 39 2002 1780 1786
9. D. Mozaffarian, R. Nye, and W.C. Levy Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE) J Am Coll Cardiol 41 2003 1933 1939
10. J.A. Ezekowitz, F.A. McAlister, and P.W. Armstrong Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure Circulation 107 2003 223 225
11. H.F. Groenveld, J.L. Januzzi, K. Damman, J. van Wijngaarden, H.L. Hillege, and D.J. van Veldhuisen Anemia and mortality in heart failure patients: a systematic review and meta-analysis J Am Coll Cardiol 52 2008 818 827
12. C.L. Murphy, and J.J. McMurray Approaches to the treatment of anaemia in patients with chronic heart failure Heart Fail Rev 13 2008 431 438
13. D.S. Silverberg, D. Wexler, A. Iaina, and D. Schwartz The role of correction of anaemia in patients with congestive heart failure: a short review Eur J Heart Fail 10 2008 819 823
14. G.M. Felker, K.F. Adams Jr., W.A. Gattis, and C.M. O'Connor Anemia as a risk factor and therapeutic target in heart failure J Am Coll Cardiol 44 2004 959 966
15. A.M. Belonje, A.A. Voors, W.H. van Gilst, and D.J. van Veldhuisen Erythropoietin in chronic heart failure Congest Heart Fail 13 2007 289 292
16. M.A. Pfeffer, E.A. Burdmann, C.Y. Chen, M.E. Cooper, D. de Zeeuw, and K.U. Eckardt A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease N Engl J Med 361 2009 2019 2032
17. A. Phrommintikul, S.J. Haas, M. Elsik, and H. Krum Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis Lancet 369 2007 381 388
18. J. Bohlius, K. Schmidlin, C. Brillant, G. Schwarzer, S. Trelle, and J. Seidenfeld Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials Lancet 373 2009 1532 1542
19. D. Moher, D.J. Cook, S. Eastwood, I. Olkin, D. Rennie, and D.F. Stroup Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses Lancet 354 1999 1896 1900
20. P. Van der Meer, H.F. Groenveld, J.L. Januzzi Jr., and D.J. van Veldhuisen Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. Heart 95 2009 1309 1314
21. A.R. Jadad, R.A. Moore, D. Carroll, C. Jenkinson, D.J. Reynolds, and D.J. Gavaghan Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17 1996 1 12
22. L. Bax, L.M. Yu, N. Ikeda, H. Tsuruta, and K.G. Moons Development and validation of MIX: comprehensive free software for meta-analysis of causal research data BMC Med Res Methodol 6 2006 50
23. A. Palazzuoli, D.S. Silverberg, A. Calabro, T. Spinelli, I. Quatrini, and M.S. Campagna beta-Erythropoietin effects on ventricular remodeling left and right systolic function, pulmonary pressure, and hospitalizations in patients affected with heart failure and anemia J Cardiovasc Pharmacol 53 2009 462 467
24. J.T. Parissis, K. Kourea, I. Andreadou, I. Ikonomidis, S. Markantonis, and K. Ioannidis Effects of darbepoetin alfa on plasma mediators of oxidative and nitrosative stress in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy Am J Cardiol 103 2009 1134 1138
25. J.K. Ghali, I.S. Anand, W.T. Abraham, G.C. Fonarow, B. Greenberg, and H. Krum Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia Circulation 117 2008 526 535
26. K. Kourea, J.T. Parissis, D. Farmakis, I. Paraskevaidis, F. Panou, and G. Filippatos Effects of darbepoetin-alpha on quality of life and emotional stress in anemic patients with chronic heart failure Eur J Cardiovasc Prev Rehabil 15 2008 365 369
27. K. Kourea, J.T. Parissis, D. Farmakis, F. Panou, I. Paraskevaidis, and K. Venetsanou Effects of darbepoetin-alpha on plasma pro-inflammatory cytokines, anti-inflammatory cytokine interleukin-10 and soluble Fas/Fas ligand system in anemic patients with chronic heart failure Atherosclerosis 199 2008 215 221
28. P. Ponikowski, S.D. Anker, J. Szachniewicz, D. Okonko, M. Ledwidge, and R. Zymlinski Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial J Am Coll Cardiol 49 2007 753 762
29. D.J. van Veldhuisen, K. Dickstein, A. Cohen-Solal, D.J. Lok, S.M. Wasserman, and N. Baker Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia Eur Heart J 28 2007 2208 2216
30. A. Palazzuoli, D. Silverberg, F. Iovine, S. Capobianco, G. Giannotti, and A. Calabro Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia Am Heart J 152 2006 1096-15
31. D.M. Mancini, S.D. Katz, C.C. Lang, J. LaManca, A. Hudaihed, and A.S. Androne Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure Circulation 107 2003 294 299
32. D.S. Silverberg, D. Wexler, D. Sheps, M. Blum, G. Keren, and R. Baruch The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study J Am Coll Cardiol 37 2001 1775 1780
33. J.T. Parissis, K. Kourea, F. Panou, D. Farmakis, I. Paraskevaidis, and I. Ikonomidis Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy Am Heart J 155 2008 751 757
34. A. Palazzuoli, D.S. Silverberg, F. Iovine, A. Calabro, M.S. Campagna, and M. Gallotta Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome Am Heart J 154 2007 645 715
35. J.R. Wilson Exercise and the failing heart Cardiol Clin 5 1987 171 181
36. T.S. Rector, S.H. Kubo, and J.N. Cohn Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo Am J Cardiol 71 1993 1106 1107
37. C.P. Green, C.B. Porter, D.R. Bresnahan, and J.A. Spertus Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure J Am Coll Cardiol 35 2000 1245 1255
38. D.J. van Veldhuisen, and J.J. McMurray Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial Eur J Heart Fail 9 2007 110 112
39. J.J. McMurray, I.S. Anand, R. Diaz, A.P. Maggioni, C. O'Connor, and M.A. Pfeffer Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial Eur J Heart Fail 11 2009 795 801
40. M.A. Pfeffer An ongoing study of anemia correction in chronic kidney disease N Engl J Med 356 2007 959 961
41. M. Tonelli, B. Hemmelgarn, T. Reiman, B. Manns, M.N. Reaume, and A. Lloyd Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis CMAJ 180 2009 E62 E71
42. A.K. Singh, L. Szczech, K.L. Tang, H. Barnhart, S. Sapp, and M. Wolfson Correction of anemia with epoetin alfa in chronic kidney disease N Engl J Med 355 2006 2085 2098
43. T.B. Drueke, F. Locatelli, N. Clyne, K.U. Eckardt, I.C. Macdougall, and D. Tsakiris Normalization of hemoglobin level in patients with chronic kidney disease and anemia N Engl J Med 355 2006 2071 2084
44. E.F. Unger, A.M. Thompson, M.J. Blank, and R. Temple Erythropoiesis- stimulating agents - time for a reevaluation N Engl J Med 362 2010 189 192
45. M. Klapholz, W.T. Abraham, J.K. Ghali, P. Ponikowski, S.D. Anker, and B. Knusel The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure Eur J Heart Fail 11 2009 1071 1077
46. S.D. Anker, C.J. Comin, G. Filippatos, R. Willenheimer, K. Dickstein, and H. Drexler Ferric carboxymaltose in patients with heart failure and iron deficiency N Engl J Med 361 2009 2436 2448
47. K. Ngo, D. Kotecha, J.A. Walters, L. Manzano, A. Palazzuoli, and D.J. van Veldhuisen Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients Cochrane Database Syst Rev 1 2010 CD007613